Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company ...

Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company ...

Basilea Pharmaceutica (BSLN) announced a strategic partnership with Phare Bio Inc., a Boston-based biotech social venture.

The TARGET (Transforming Antibiotic R&D with Generative AI to stop Emerging Threats) Project is enabling Phare Bio to rapidly scale and optimize its generative AI discovery platform to thwart the ...

Phare Bio has been awarded $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). The biotech startup will use the money to advance its antibiotic discovery initiative.

MURRAY, Utah, Oct. 22, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, today announced the launch of the Phare Operating System, healthcare’s first ...

MURRAY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), an industry leader in managing and intelligently automating healthcare revenue management, today announced that it has ...

Phare is no ordinary circus, but an edgy, alternative, down-to-earth, all-singing-and-dancing Cambodian circus in the tradition of Cirque du Soleil. A contemporary circus without animals, the cast of ...

Delivers on R1’s Long-Term Investments in People and Technology to Transform the Revenue Cycle Through Sustained, AI-Driven Innovation MURRAY, Utah, Oct. 22, 2025 (GLOBE NEWSWIRE) -- R1 ("R1” or the ...